Trial Search Results
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
- Primary: To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib
- Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with gemcitabine and erlotinib
Stanford is currently not accepting patients for this trial.